Mesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says

MT Newswires Live04-10

Mesoblast (ASX:MSB) recently held its R&D day for the year, where it provided updates on the rollout of its Ryoncil product, among others, Jefferies said in a Thursday note.

The investment firm particularly noted Mesoblast's fiscal 2026 net revenue guidance of between $110 million and $120 million and goal of doubling its Ryoncil net sales in the US.

Jefferies said other updates that stood out are the company's potential US launch of chronic low back pain in the second quarter of 2028, if approved, and the start of the phase 3 adult steroid-refractory acute GVHD trial in the second quarter of this year.

The investment firm updated the start of chronic low back pain product revenue to fiscal 2029 from fiscal 2027.

Jefferies retained its buy rating on Mesoblast and cut its price target to AU$2.80 from AU$3.20.

Mesoblast's shares jumped almost 5% in recent Friday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626316336?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 11:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626316336","market":"nz","top_or_hot":-1,"title":"Mesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) recently held its R&amp;D day for the year, where it provided updates on the rollout of its Ryoncil product, among others, Jefferies said in a Thursday note.</p><p>The investment firm particularly noted Mesoblast's fiscal 2026 net revenue guidance of between $110 million and $120 million and goal of doubling its Ryoncil net sales in the US.</p><p>Jefferies said other updates that stood out are the company's potential US launch of chronic low back pain in the second quarter of 2028, if approved, and the start of the phase 3 adult steroid-refractory acute GVHD trial in the second quarter of this year.</p><p>The investment firm updated the start of chronic low back pain product revenue to fiscal 2029 from fiscal 2027.</p><p>Jefferies retained its buy rating on Mesoblast and cut its price target to AU$2.80 from AU$3.20.</p><p>Mesoblast's shares jumped almost 5% in recent Friday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-10 11:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) recently held its R&amp;D day for the year, where it provided updates on the rollout of its Ryoncil product, among others, Jefferies said in a Thursday note.</p><p>The investment firm particularly noted Mesoblast's fiscal 2026 net revenue guidance of between $110 million and $120 million and goal of doubling its Ryoncil net sales in the US.</p><p>Jefferies said other updates that stood out are the company's potential US launch of chronic low back pain in the second quarter of 2028, if approved, and the start of the phase 3 adult steroid-refractory acute GVHD trial in the second quarter of this year.</p><p>The investment firm updated the start of chronic low back pain product revenue to fiscal 2029 from fiscal 2027.</p><p>Jefferies retained its buy rating on Mesoblast and cut its price target to AU$2.80 from AU$3.20.</p><p>Mesoblast's shares jumped almost 5% in recent Friday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MESO","symbol_name":"Mesoblast Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2626316336","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626316336","pubTimestamp":1775792852,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  recently held its R&D day for the year, where it provided updates on the rollout of its Ryoncil product, among others, Jefferies said in a Thursday note.The investment firm particularly noted Mesoblast's fiscal 2026 net revenue guidance of between $110 million and $120 million and goal of doubling its Ryoncil net sales in the US.Jefferies said other updates that stood out are the company's potential US launch of chronic low back pain in the second quarter of 2028, if approved, and the start of the phase 3 adult steroid-refractory acute GVHD trial in the second quarter of this year.The investment firm updated the start of chronic low back pain product revenue to fiscal 2029 from fiscal 2027.Jefferies retained its buy rating on Mesoblast and cut its price target to AU$2.80 from AU$3.20.Mesoblast's shares jumped almost 5% in recent Friday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MESO":"Mesoblast Limited"},"translate_title":"杰富瑞表示，Mesoblast 2026财年净收入预计将高达1.2亿美元","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5},"content_text":"Mesoblast (ASX:MSB) recently held its R&D day for the year, where it provided updates on the rollout of its Ryoncil product, among others, Jefferies said in a Thursday note.The investment firm particularly noted Mesoblast's fiscal 2026 net revenue guidance of between $110 million and $120 million and goal of doubling its Ryoncil net sales in the US.Jefferies said other updates that stood out are the company's potential US launch of chronic low back pain in the second quarter of 2028, if approved, and the start of the phase 3 adult steroid-refractory acute GVHD trial in the second quarter of this year.The investment firm updated the start of chronic low back pain product revenue to fiscal 2029 from fiscal 2027.Jefferies retained its buy rating on Mesoblast and cut its price target to AU$2.80 from AU$3.20.Mesoblast's shares jumped almost 5% in recent Friday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626316336","isCrawlerRequest":true}